Open Accessibility Menu
Hide

Galleri Test by GRAIL

1 Test That Can Screen for more than 50 cancers

The earlier cancer is diagnosed, the more treatment options you may have. That’s why doctors recommend certain routine cancer screenings, such as colonoscopy, mammography, or PSA tests. However, many types of cancer are only found at more advanced stages, either because they don’t initially have symptoms or because there is no routine test to diagnose them.

The Galleri® test changes all that. This exciting medical breakthrough is a new proactive tool in finding cancer early. This multi-cancer early detection test can be done as a simple annual blood test that screens for a “fingerprint” of some of the deadliest cancers before they become symptomatic, including those without recommended screening tests today. Community Memorial Healthcare is delighted to be the first healthcare system in Ventura County to make the Galleri® test available to local physicians and their patients.

The Galleri® test can screen for a signal shared by more than 50 types of cancer, including 12 cancers responsible for 2/3 of cancer deaths:*

  • Anus
  • Bladder
  • Colon/rectum
  • Esophagus
  • Head & neck
  • Liver/bile duct
  • Lung
  • Lymphoma
  • Ovary
  • Pancreas
  • Plasma cell neoplasm
  • Stomach

About the Galleri® Test

In a clinical study, the Galleri® test was able to detect a fingerprint shared by some of the deadliest cancers, including some that do not have a recommended screening. The test has several advantages:

  • Galleri® is the one early detection test that can screen for a fingerprint shared by multiple cancers through a single simple blood draw 1
  • The test is so easy to administer, it can be incorporated into a wellness visit
  • If a cancer signal is detected, the results can predict the tissue type or organ associated with
    the signal 1

Who should get the Galleri® test?

The Galleri® test may be right for you if you are over the age of 50 and have a family history of cancer, have other risk factors for cancer, or are immunocompromised. The Galleri® test requires a physician's order. Ask your doctor if you are a good candidate for the test.

Community Memorial, in partnership with GRAIL, is the first health system based in Ventura or Santa Barbara county to offer the test at a discounted price of $799. The Galleri® test typically costs $949 as an out-of-pocket expense.

* 1 Klein EA, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-1177. DOI: doi.org/10.1016/j.
annonc.2021.05.806

Important Safety Information

The Galleri® test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri® test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri® is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri® is not
recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment. Results should be interpreted by a healthcare provider in the context of medical history,
clinical signs and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically
established procedures (e.g. imaging) to confirm cancer. If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including
due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is
present) test results do occur. Rx only.

Laboratory / Test Information

GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The Galleri® test was
developed, and its performance characteristics were determined by GRAIL. The Galleri® test has not been cleared or approved by the Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri® test is intended for clinical purposes.

Payment Options

The Galleri(R) test may be eligible for FSA or HSA reimbursement. Contact your FSA or HSA administrator for more information. Interest-free payment plans are available for up to 12 months through GRAIL. Please contact GRAIL billing support at 1-855-775-3613.